Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other 1Gastrointestinal 1

Conditions

Multiple Myeloma 930Lymphoma 113Neoplasms, Plasma Cell 93Recurrence 92Lymphoma, Non-Hodgkin 68Hematologic Neoplasms 62Immunoglobulin Light-chain Amyloidosis 61Neoplasms 54Smoldering Multiple Myeloma 51Leukemia, Myeloid, Acute 51Leukemia 51Myelodysplastic Syndromes 48Leukemia, Lymphocytic, Chronic, B-Cell 46Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Hodgkin Disease 38Leukemia, Plasma Cell 26Myeloproliferative Disorders 24Monoclonal Gammopathy of Undetermined Significance 23Lymphoma, Large B-Cell, Diffuse 23Lymphoma, Mantle-Cell 22Leukemia, Myelogenous, Chronic, BCR-ABL Positive 22Breast Neoplasms 22Amyloidosis 22Primary Myelofibrosis 21Lymphoma, Follicular 21Waldenstrom Macroglobulinemia 20Ovarian Neoplasms 18Lymphoma, B-Cell, Marginal Zone 17Lymphoma, B-Cell 17Colorectal Neoplasms 16

Interventions

isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hepatomegaly × Plasma cell × 1 year × Clear all
NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

SWOG Cancer Research Network

Phase 2 Completed
43 enrolled 23 charts
GastrointestinalOtherPlasma cell

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

Data powered by HemOnc (CC BY 4.0) Colophon âš¡